NEOG vs IDXX vs BCAL vs QDEL vs NVAX

For growth investors, Novavax, Inc.

(NVAX) is the stronger pick with 64. 7% revenue growth year-over-year, versus -3. 2% for Neogen Corporation (NEOG). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate IDEXX Laboratories, Inc. (IDXX) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, QuidelOrtho Corporation is actually cheaper at 6. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Southern California Bancorp wins at 0. 36x versus IDEXX Laboratories, Inc. 's 2. 76x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Southern California Bancorp (BCAL) delivered a total return of +42.

7%, compared to -94. 8% for Novavax, Inc. (NVAX). Over 10 years, the gap is even starker: IDXX returned +556. 2% versus NVAX's -90. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Southern California Bancorp (BCAL) is the lower-risk stock at 0.

90β versus QuidelOrtho Corporation's 2. 59β — meaning QDEL is approximately 189% more volatile than BCAL relative to the S&P 500. On balance sheet safety, Southern California Bancorp (BCAL) carries a lower debt/equity ratio of 12% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Novavax, Inc.

(NVAX) is pulling ahead at 64. 7% versus -3. 2% for Neogen Corporation (NEOG). On earnings-per-share growth, the picture is similar: Southern California Bancorp grew EPS 777. 3% year-over-year, compared to -114. 6% for Neogen Corporation. Over a 3-year CAGR, NEOG leads at 19. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -122. 1% for Neogen Corporation — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Southern California Bancorp (BCAL) is the more undervalued stock at a PEG of 0. 36x versus IDEXX Laboratories, Inc. 's 2. 76x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6. 4x forward P/E versus 39. 5x for IDEXX Laboratories, Inc. — 33. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVAX: 95. 0% to $18. 00.

In this comparison, BCAL (0.

5% yield) pays a dividend. NEOG, IDXX, QDEL, NVAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Southern California Bancorp (BCAL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

90), 0. 5% yield, +133. 6% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BCAL: +133. 6%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NEOG (Healthcare) and IDXX (Healthcare) and BCAL (Financial Services) and QDEL (Healthcare) and NVAX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NEOG is a small-cap quality compounder stock; IDXX is a mid-cap quality compounder stock; BCAL is a small-cap high-growth stock; QDEL is a small-cap quality compounder stock; NVAX is a small-cap high-growth stock. BCAL pays a dividend while NEOG, IDXX, QDEL, NVAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.